

AMENDMENTS TO THE CLAIMS

(deletions shown by strikethrough; additions underlined)

What is claimed is:

1. (CURRENTLY AMENDED) A method of inducing an immune response that increases HDL cholesterol levels in a mammal exhibiting or at risk of exhibiting low levels of serum HDL cholesterol comprising administering to said mammal an immunogenic composition comprising a full-length cholesterol ester transfer protein (CETP) and further comprising a carrier linked to said protein and wherein said immunogenic composition is capable of raising antibodies that recognize said mammal's endogenous CETP.
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (CURRENTLY AMENDED) The method of Claim [[6]]1, wherein said carrier is selected from the group consisting of keyhole limpet hemocyanin (KLH), ovalbumin, and Diphteria toxoid.
8. (CURRENTLY AMENDED) The method of any one of claims 1, 2, 5, 6, and Claim 1 or 7, wherein said composition is administered with an adjuvant.
9. (PREVIOUSLY PRESENTED) The method of Claim 1, wherein said administration is repeated.
10. (CURRENTLY AMENDED) The method of Claim [[6]]1, wherein said full-length CETP is the native CETP of said mammal.

11. (CURRENTLY AMENDED) The method of Claim 1 or 6, wherein said full-length CETP is a human CETP.
12. (CURRENTLY AMENDED) The method of Claim 1 or 6, wherein said full-length CETP is a rabbit CETP.
13. (CURRENTLY AMENDED) The method of Claim 1 or 6, wherein said full-length CETP differs from the native CETP of said mammal.